Is Revolution Medicines (RVMD) Fully Valued Following Its FDA Filing Win?
Revolution Medicines (RVMD) is back in focus after the FDA accepted its New Drug Application for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma, following Phase 3 RASolute 302 survival and quality of life data.
See our latest analysis for Revolution Medicines.
At a share price of US$187.53, Revolution Medicines has seen the share price rise 34.45% over the past 90 days and 137.32% year to date, with a 1 year total shareholder return above 400%. This suggests the FDA and EMA progress on daraxonrasib is feeding into stronger momentum and shifting investor perceptions of future risk and reward.
If this kind of drug development story has your attention, it can be worth scanning other healthcare-focused opportunities using our screener for 41 healthcare AI stocks
After a move like this, the key tension for Revolution Medicines is clear. Are investors now overpaying for a high profile pipeline win, or is the current price still fair once the valuation is unpacked next?
Most Popular Narrative: 8.2% Undervalued
Against the last close at $187.53, the most followed narrative pegs Revolution Medicines’ fair value at about $204.38, framing today’s price as a discount that rests on a very specific growth and margin story.
The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio, which could influence long term revenue growth if multiple registrational programs convert to approved therapies.
Eight ongoing or planned Phase III registrational trials and clinical experience in more than 2,500 patients create multiple data points over the next few years that could change how investors view the durability and scale of the pipeline, with potential implications for future revenue visibility and earnings power.
Want to see what underpins that pipeline driven valuation gap? The narrative leans on rapid revenue build, higher margins and a rich future earnings multiple. Curious which specific assumptions make $204.38 look reasonable on a discounted basis.
Result: Fair Value of $204.38 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Revolution Medicines story still depends on heavy cash use with no current revenue and on multiple RAS focused trials that could disappoint or face delays.
Find out about the key risks to this Revolution Medicines narrative.
Next Steps
With Revolution Medicines attracting strong opinions on both risk and reward, it may be useful to move quickly and test the narrative against your own view using the full breakdown of 2 key rewards and 2 important warning signs
Looking for more investment ideas beyond Revolution Medicines?
If Revolution Medicines has sharpened your focus, do not stop here. Broader stock ideas can help you balance risk, spot opportunities and stress test your overall approach.
- Spot potential value opportunities early by scanning companies that appear mispriced relative to their fundamentals using the 55 high quality undervalued stocks.
- Strengthen your income side by reviewing businesses with higher yields through the 9 dividend fortresses.
- Dial down portfolio risk by shortlisting companies with steadier profiles using the 81 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com